

Discovery of first-in-Class WNK3 targeted selective inhibitor for cancer immunotherapy

Checkmate Therapeutics Inc.



ONCOLOGY	Hit
Product Type	Small molecule (kinase inhibitor)
Indication	Solid tumor
Target	WNK3 (WNK lysine deficient protein kinase 3)
MoA (Mechanism of Action)	WNK3 inhibition elicits antitumor immunity by suppressing PD-L1 expression on tumor cells and activating T-cell function
Competitiveness	<ol style="list-style-type: none"> 1. First-in-Class WNK3 selective inhibitor 2. Highly Potent and Selective to WNK3 <ul style="list-style-type: none"> - Compound CX003 demonstrates nM potency of WNK3 inhibition and excellent selectivity against WNK1. 3. Superior safety <ul style="list-style-type: none"> - It also demonstrates enhanced safety in normal cell lines. 4. Concurrent impact on cancer and immune cells <ul style="list-style-type: none"> - It suppresses PD-L1 in cancer cells and activates T-Cells
Development Stage	Hit
Route of Administration	Oral administration